Aclaris Announces Pricing of Initial Public Offering
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Aclaris Therapeutics (ACRS) IPO Opens 9% Higher
October 7, 2015 10:07 AM EDTToday's IPO for Aclaris Therapeutics (NASDAQ: ACRS) opened for trading at $11.94 after pricing 5,000,000 shares of its common stock at a price to the public of $11.00 per share, below the expected $14-$16 range.
Jefferies LLC and Citigroup Global Markets Inc. are acting as joint... More
